ÂÜÀòÂÒÂ×

Michael Sidler is a seasoned venture capital professional and co-founder of redalpine, where Michael has served as General Partner since December 2006, focusing on investments in high-tech companies across ICT and Life Sciences. Additionally, Michael holds various board positions, including Board Member at Araris Biotech AG, Advisory Board Member at Maximon, and Member of the Board at aktiia and Memo Therapeutics AG. Michael also contributes as Board Observer at ImmunOs Therapeutics AG and has been involved with Lunaphore and Disruption Disciples. Previously, Michael chaired the Seed & Venture Capital Chapter of SECA, enhancing the private equity and venture capital landscape in Switzerland. Michael earned a PhD in Plant Molecular Biology from the University of Zurich and completed an Executive Program at Singularity University in 2019.